| |
CTL
|
AD
|
|---|
|
Time point
|
1
|
2
|
3
|
1
|
2
|
3
|
|
No.
|
15
|
12
|
4
|
57
|
57
|
32
|
|
Age, years
|
86 [79, 87]
|
88 [83, 90]
|
90 [89, 95]
|
83 [77, 88]
|
84 [78, 89]
|
87 [79, 89]
|
|
Gender, M/F
|
6/9
|
7/5
|
3/1
|
22/35
|
22/35
|
11/21
|
|
MMSE
|
29 [28.5, 30]
|
29 [28, 30]
|
29 [28, 29.3]
|
17 [9, 22]
|
14 [6, 20]
|
8 [4, 15]
|
|
APOE, ε4 carriers
|
5/14 (36%)
|
5/12 (42%)
|
2/4 (50%)
|
33/54 (61%)
|
33/54 (61%)
|
19/32 (59%)
|
|
NfL, pg/mL
|
29 [23, 34.5]
|
33 [29.3, 47]
|
39.3 [33, 45]
|
42 [33, 57]
|
48.3 [32, 67]
|
65 [47.3, 87]
|
|
Time to post-mortem, years
|
7 [3, 8]
|
7 [4, 8]
|
6.5 [6, 8]
|
4 [3, 6]
|
3 [2, 5]
|
2 [1, 3]
|
|
Braak staging
|
Transentorhinal (I/II)
|
8
|
7
|
3
|
2
|
2
|
0
|
|
Limbic (III/IV)
|
4
|
3
|
0
|
11
|
11
|
4
|
|
Isocortical (V/VI)
|
3
|
2
|
1
|
44
|
44
|
28
|
- MMSE was found to be lower among CTL subjects, as compared to AD, across all three time points (p < 0.001)
- Plasma NfL was higher among AD subjects, relative to controls, at time point 1 (p < 0.01) and at both second and third time points (p < 0.05)
